

C 2 D  
where R is Cl or Br and ~~its~~ non-toxic pharmaceutically acceptable salts and N-oxides and mixtures thereof.

3  
25. A compound according to claim ~~24~~<sup>29</sup> which is the trans-isomer of 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethyl-  
amino)ethoxy]phenyl]-1-butene <sup>or a</sup> ~~and its~~ non-toxic  
pharmaceutically acceptable salts <sup>thereof</sup>

D 4 26. A compound according to claim ~~24~~<sup>29</sup> which is the citrate of the trans-isomer of 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene.--

Claims 9 and 13, line 1 of each: delete "21" and insert --24--.

Claim 19, line 6: delete "21" and insert --24--.

Claim 23, line 3: delete "21" and insert --24--.

#### REMARKS

The claims of the application have been limited to preferred compounds of the invention, 4-chloro-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene and 4-bromo-1,2-diphenyl-1-[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene, and non-toxic pharmaceutically acceptable salts thereof (claims 24, 9 and 13); to the trans-isomer of the 4-chloro compound (claim 25); to the citrate of the trans-isomer of the 4-chloro compound (claim 26); to a method of producing an oestrogenic, anti-oestrogenic or progestanic